Home General Bharat Biotech’s Covid nasal vaccine gets regulator’s nod for holding phase 2, 3 clinical trials

Bharat Biotech’s Covid nasal vaccine gets regulator’s nod for holding phase 2, 3 clinical trials

by Manisha Sen
0 comment

New Delhi, August 13 (PTI): The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator’s nod for conducting phase 2 and 3 clinical trials, the Department of Biotechnology said on Friday.

Representative Image.

Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, it said.

“Bharat Biotech’s intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials,” the DBT said.

This is the first of its kind COVID-19 jab to undergo human clinical trials in India.

BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.

Bharat Biotech has in-licensed technology from Washington University in St Louis, US.


Disclaimer :- This story has not been edited by The Sen Times staff and is auto-generated from news agency feeds.
Source: Reuters


You may also like

About Us

The Sen Times, India’s first and largest online newspaper established its place in the media scene of India in 2010. It started its online journey in 2012 with a sense of challenge and a feeling of humility to serve the bureaucrats and public servants as a truly independent newspaper for them.

Latest News

Popular News

Copyright © 2022 Sen Times Group Pvt. Ltd. All rights reserved.
%d bloggers like this: